Investigational drug · Phase 2
LY188011
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Neoplasms, Child, Adolescent.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3,576
Any phase or sponsor naming "LY188011"
First trial start
2016
May 19, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "LY188011", any sponsor or status.
Conditions studied
As listed on its trial records.
- Neoplasms
- Child
- Adolescent
- Biliary Tract Cancer
- Metastatic Cancer
- Advanced Cancer
Approved drugs for the same conditions: Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "LY188011" as an intervention, largest first.
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruiting
National Cancer Institute (NCI)NIH
NCT02194738 · 7,458 participants · Start Sep 26, 2014 · Primary completion Dec 3, 2025
Drug: Carboplatin; Cisplatin and 8 more · For: Stage IB Lung Non-Small Cell Carcinoma AJCC v7; Stage II Lung Non-Small Cell Cancer AJCC v7; Stage IIA Lung Cancer AJCC v8 and 4 more
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,660 sites in all
- Combination Chemotherapy in Treating Women Who Have Undergone Surgery for Node-Positive Breast CancerPivotal-lookingCompleted
NSABP Foundation IncResearch network
NCT00093795 · 4,894 participants · Start Oct 2004 · Primary completion Mar 2012
Drug: Cyclophosphamide; Docetaxel and 3 more · For: Breast Cancer
Sites: Birmingham, Alabama; Anchorage, Alaska; Stuart, Florida · 12 sites in all
Sungkyunkwan UniversityAcademic, hospital or other
NCT04115410 · 4,724 participants (planned) · Start Jul 1, 2020 · Primary completion Sep 23, 2021
Drug: PD-1 inhibitor; Chemotherapy Drugs, Cancer · For: Carcinoma, Non-Small-Cell Lung; Immune-Related Adverse Events
- Combination Chemotherapy in Treating Patients With Stage III or Stage IV Ovarian Epithelial Cancer or Primary Peritoneal CancerPivotal-lookingCompleted
Gynecologic Oncology GroupResearch network
NCT00011986 · 4,312 participants · Start Jan 2001 · Primary completion Mar 2010
Drug: Paclitaxel; Carboplatin and 3 more · For: Primary Peritoneal Carcinoma; Stage III Ovarian Cancer; Stage IV Ovarian Cancer
Sites: Philadelphia, Pennsylvania
- Simultaneous Study of Gemcitabine-Docetaxel Combination Adjuvant Treatment, as Well as Extended Bisphosphonate and Surveillance-TrialPivotal-lookingCompleted
Ludwig-Maximilians - University of MunichAcademic, hospital or other
NCT02181101 · 3,754 participants · Start Sep 2005 · Primary completion Sep 2013
Drug: FEC-DocGemzar adjuvant chemotherapy; FEC-Doc adjuvant chemotherapy and 2 more · For: Breast Neoplasms
Sites: Munich, Germany
Bristol-Myers SquibbBristol Myers Squibb (BMY)
NCT02477826 · 2,747 participants · Start Aug 5, 2015 · Primary completion Oct 25, 2024
Drug: Nivolumab; Ipilimumab and 5 more · For: Non-Small Cell Lung Cancer
Sites: Mobile, Alabama; San Francisco, California; New Haven, Connecticut · 290 sites in all
Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo CompanyDaiichi Sankyo (DSNKY)
NCT05945732 · 2,295 participants (planned) · Start Oct 24, 2023 · Primary completion Dec 31, 2030
Drug: Trastuzumab deruxtecan · For: Unresectable Breast Cancer; Metastatic Breast Cancer; HER2-low Expressing Breast Cancer and 1 more
Sites: Graz, Austria; Innsbruck, Austria; Klagenfurt, Austria · 216 sites in all
University of ZurichAcademic, hospital or other
NCT00490360 · 2,007 participants · Start Oct 2001
Drug: Gemcitabine / Cisplatin · For: Cancer of the Pancreatic Head
Sites: Zurich, Switzerland
- Carboplatin/Paclitaxel +/-Gemcitabine in Treating Patients With Ovarian Epithelial or Fallopian Tube CancerPivotal-lookingCompleted
AGO Study GroupAcademic, hospital or other
NCT00052468 · 1,742 participants · Start Aug 2002 · Primary completion Jul 2009
Drug: TCG; TC · For: Fallopian Tube Cancer; Ovarian Cancer
Sites: Copenhagen, Denmark; Paris, France; Bremen, Germany · 17 sites in all
- A Randomized Phase 3 Trial of Pemetrexed and Cisplatin Versus Gemcitabine and Cisplatin in Patients With Locally Advanced or Metastatic Non Small Cell Lung CancerPivotal-lookingCompleted
Eli Lilly and CompanyEli Lilly (LLY)
NCT00087711 · 1,713 participants · Start Jul 2004 · Primary completion Jan 2007
Drug: pemetrexed; gemcitabine and 1 more · For: Non Small Cell Lung Carcinoma
Sites: Sacramento, California; Torrance, California; Jacksonville, Florida · 134 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Qishen Yangxin Granule ameliorates cardiac function and ventricular remodeling in dilated cardiomyopathy by attenuating inflammation and myocardial fibrosis.
Tao S, Yu L, Li J, et al. · Phytomedicine 2026
- A phase II study of gemcitabine (gemzar, LY188011) in the treatment of recurrent or persistent endometrial carcinoma: a gynecologic oncology group study.
Tait DL, Blessing JA, Hoffman JS, et al. · Gynecol Oncol 2011
- A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.
Kunikane H, Kurita Y, Watanabe K, et al. · Int J Clin Oncol 2001
- Phase II trial of gemcitabine in patients with previously untreated metastatic cancer of the esophagus or gastroesophageal junction.
Sandler AB, Kindler HL, Einhorn LH, et al. · Ann Oncol 2000
- [Late phase II study of LY188011 (gemcitabine hydrochloride) in patient with non-small-cell lung cancer. Gemcitabine Late Phase II Cooperative Study Group A)].
Fukuoka M, Negoro S, Kudo S, et al. · Gan To Kagaku Ryoho 1996
Also in development for Neoplasms
- CetrelimabJNJ-63723283Phase 38 trials
Johnson & Johnson (Janssen) · Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Neoplasms
- VT3989Phase 32 trials
Vivace Therapeutics, Inc · Pleural Mesothelioma, Mesothelioma, Solid Tumor, Adult
- [177Lu]Lu-NeoBLutetium NeoB, [177Lu]-NeoBPhase 22 trials
Novartis · Breast Cancer, Neoplasms
- [68Ga]Ga-NeoBGallium NeoB, [68Ga]-NeoBPhase 22 trials
Novartis · Breast Cancer, Neoplasms
- Checkpoint InhibitorPhase 22 trials
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- AdAPT-001Phase 21 trial
EpicentRx, Inc. · Solid Tumor, Adult, Cancer, Neoplasms
- CORT125236NenocorilantPhase 21 trial
Corcept Therapeutics · Neoplasms
- E7386Phase 21 trial
Eisai · Endometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from Eli Lilly.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.